接受造血干细胞移植患者住院姑息治疗干预的多中心随机试验
在接受自体或异基因造血干细胞移植的成人中开展多中心随机试验,比较住院姑息治疗干预与常规照护。干预组在移植住院期间每周与姑息治疗临床医生会面两次。第2周时干预组患者生活质量更优、抑郁和创伤后应激障碍症状更少,焦虑无显著差异;创伤后应激障碍症状的改善持续至移植后6个月。
要点
- 移植住院期间每周两次姑息治疗会诊可改善第2周生活质量、抑郁和创伤后应激障碍症状
- 第2周患者焦虑评分两组间无显著差异
- 创伤后应激障碍症状在移植后6个月内的下降斜率干预组更陡
核心结论
- 姑息治疗使患者生活质量、抑郁和创伤后应激障碍症状获得实质性改善,且对创伤后应激障碍症状的效应持续至移植后6个月。
研究设计与样本
- 多中心随机试验,在三个学术机构纳入接受自体或异基因造血干细胞移植的成人,随机分为住院姑息治疗干预组或常规照护组;干预组在移植住院期间每周与姑息治疗临床医生会面两次,常规照护组可按标准照护转诊姑息治疗。
- 2018年10月至2022年7月期间入组符合条件患者的68.7%(360/524)。
- 主要终点为住院第2周患者生活质量(生活质量谷值期);采用线性回归校正基线评分评估第2周患者报告结局,采用线性混合效应模型纵向评估干预效果。
主要发现
- 第2周时,与常规照护组相比,干预组患者生活质量更优(校正均数差B=6.3;SE=0.1;P<.001)。
- 第2周时,与常规照护组相比,干预组患者抑郁评分更低(B=-1;SE=0.4;P=.026)。
- 第2周时,与常规照护组相比,干预组患者创伤后应激障碍症状更少(B=-1.9;SE=0.9;P=.046)。
- 第2周时,患者报告的焦虑评分两组间无显著差异。
- 纵向分析中,干预组患者在移植后6个月内创伤后应激障碍症状下降斜率更陡(斜率差=-0.9;SE=0.7;P=.012);其余患者报告结局纵向比较两组间均无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients undergoing hematopoietic stem cell transplantation (HSCT) and their caregivers endure immense physical and psychological symptoms, which result in quality-of-life (QOL) impairments during HSCT. METHODS: We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) intervention or usual care. Intervention patients met with PC clinicians twice weekly during the HSCT hospitalization. Patients assigned to usual care could be referred to PC as per standard of care. We assessed QOL (patient: Functional Assessment of Cancer Therapy-Bone Marrow Transplant; caregiver: Caregiver-Oncology-QOL), depression and anxiety symptoms (Hospital-Anxiety-and-Depression-Scale), and patients' post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist) at baseline, week 2, and 3 and 6 months post-HSCT. The primary end point was patients' QOL at week 2 during hospitalization when patients experience their QOL nadir. We used linear regression, adjusting for baseline scores, to evaluate the effect of the intervention on patient-reported outcomes at week 2. We used linear mixed-effect models to assess the effect of the intervention on study outcomes longitudinally. RESULTS: We enrolled 68.7% (360/524) of eligible patients between October 2018 and July 2022. Compared with those receiving usual care, patients receiving the intervention reported better QOL (adjusted mean difference [B], 6.3; SE, 0.1; P < .001), lower depression (B, -1; SE, 0.4; P = .026), and fewer PTSD symptoms (B, -1.9; SE, 0.9; P = .046) at week 2. Patient-reported anxiety did not differ significantly between groups at week 2. In longitudinal analyses, patients receiving the intervention reported a steeper decline in PTSD symptoms over 6 months post-HSCT (slope difference, -0.9; SE, 0.7; P = .012). All other patient-reported outcomes did not differ longitudinally between the groups. CONCLUSION: PC led to substantial improvements in patients' QOL, depression, and PTSD symptoms with sustained effects on PTSD symptoms up to 6 months post-HSCT.
引用
- El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation. J Clin Oncol. 2025. PMID: 40549982. doi:10.1200/JCO-25-00378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。